Literature DB >> 33564180

Circulating prorenin: its molecular forms and plasma concentrations.

Kazumi Fujimoto1,2, Sayuki Kawamura1, Satoru Bando1, Yuji Kamata1, Yoshio Kodera2, Masayoshi Shichiri3.   

Abstract

The renin-angiotensin-aldosterone system plays pivotal roles in the maintenance of fluid homeostasis and in the pathophysiology of major human diseases. However, the molecular forms of plasma renin/prorenin have not been fully elucidated, and measurements of plasma prorenin levels are still unavailable for clinical practice. We attempted to evaluate the molecular forms of human plasma prorenin and to directly measure its concentration without converting it to renin to determine its activity. Polyacrylamide gel electrophoresis and subsequent immunoblotting using antibodies that specifically recognise prosegment sequences were used to analyse its molecular forms in plasma. We also created a sandwich enzyme-linked immunosorbent assay suitable for directly quantifying the plasma concentration. The plasma level in healthy people was 3.0-13.4 μg/mL, which is from 3 to 4 orders of magnitude higher than the levels reported thus far. Plasma immunoreactive prorenin consists of three major distinct components: a posttranslationally modified full-length protein, an albumin-bound form and a smaller protein truncated at the common C-terminal renin/prorenin portion. In contrast to plasma renin activity, plasma prorenin concentrations were not affected by the postural changes of the donor. Hence, plasma prorenin molecules may be posttranslationally modified/processed or bound to albumin and are present in far higher concentrations than previously thought.

Entities:  

Keywords:  ELISA; Plasma binding protein; Plasma concentration; Plasma molecular form; Prorenin

Mesh:

Substances:

Year:  2021        PMID: 33564180     DOI: 10.1038/s41440-020-00610-0

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  40 in total

1.  Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II.

Authors:  Jasper J Saris; Peter A C 't Hoen; Ingrid M Garrelds; Dick H W Dekkers; Johan T den Dunnen; Jos M J Lamers; A H Jan Danser
Journal:  Hypertension       Date:  2006-08-28       Impact factor: 10.190

2.  High plasma prorenin in diabetes mellitus and its correlation with some complications.

Authors:  A A Franken; F H Derkx; A J Man in't Veld; W C Hop; G H van Rens; E Peperkamp; P T de Jong; M A Schalekamp
Journal:  J Clin Endocrinol Metab       Date:  1990-10       Impact factor: 5.958

3.  Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity.

Authors:  F H Derkx; R J de Bruin; J M van Gool; M J van den Hoek; C C Beerendonk; F Rosmalen; P Haima; M A Schalekamp
Journal:  Clin Chem       Date:  1996-07       Impact factor: 8.327

4.  Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin.

Authors:  Genevieve Nguyen; Françoise Delarue; Céline Burcklé; Latifa Bouzhir; Thomas Giller; Jean-Daniel Sraer
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

5.  Inhibition of human renin by synthetic peptides derived from its prosegment.

Authors:  F Cumin; G Evin; J A Fehrentz; R Seyer; B Castro; J Menard; P Corvol
Journal:  J Biol Chem       Date:  1985-08-05       Impact factor: 5.157

6.  Activation of human inactive ("pro-") renin by cathepsin D and pepsin.

Authors:  B J Morris
Journal:  J Clin Endocrinol Metab       Date:  1978-01       Impact factor: 5.958

Review 7.  Activity assays and immunoassays for plasma Renin and prorenin: information provided and precautions necessary for accurate measurement.

Authors:  Duncan J Campbell; Juerg Nussberger; Michael Stowasser; A H Jan Danser; Alberto Morganti; Erik Frandsen; Joël Ménard
Journal:  Clin Chem       Date:  2009-03-05       Impact factor: 8.327

8.  Characterization of angiotensin peptides in plasma of anephric man.

Authors:  D J Campbell; A Kladis; S L Skinner; J A Whitworth
Journal:  J Hypertens       Date:  1991-03       Impact factor: 4.844

9.  Plasma renin activity and plasma prorenin assays.

Authors:  J E Sealey
Journal:  Clin Chem       Date:  1991-10       Impact factor: 8.327

10.  Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms.

Authors:  Y Huang; S Wongamorntham; J Kasting; D McQuillan; R T Owens; L Yu; N A Noble; W Border
Journal:  Kidney Int       Date:  2006-01       Impact factor: 18.998

View more
  2 in total

1.  Plasma and serum prorenin concentrations in diabetes, hypertension, and renal disease.

Authors:  Sayuki Kawamura; Kazumi Fujimoto; Akinori Hayashi; Yuji Kamata; Ibuki Moriguchi; Naoyuki Kobayashi; Masayoshi Shichiri
Journal:  Hypertens Res       Date:  2022-06-10       Impact factor: 5.528

2.  GIP_HUMAN[22-51] is a new proatherogenic peptide identified by native plasma peptidomics.

Authors:  Tsuguto Masaki; Yoshio Kodera; Michishige Terasaki; Kazumi Fujimoto; Tsutomu Hirano; Masayoshi Shichiri
Journal:  Sci Rep       Date:  2021-07-14       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.